• Targeting O-GlcNAcylation: OSMI-1 and the Future of Ferropto

  2026-06-20

  This thought-leadership article explores the mechanistic and translational opportunities unlocked by OSMI-1, a potent O-GlcNAc transferase inhibitor, in ferroptosis and placental biology. Integrating recent discoveries on the HUWE1-TfR1 axis in preeclampsia, we assess competitive research strategies, highlight protocol essentials, and provide a forward view on clinical and experimental innovation. Distinct from standard product pages, this piece bridges molecular, experimental, and strategic domains for the translational research community.

• Acetoacetic Acid Sodium Salt: Benchmark for Energy Metabolis

  2026-06-19

  Acetoacetic acid sodium salt is a validated ketone body metabolite crucial for energy metabolism and diabetes research. Verified by high-purity analytical methods, it serves as a reliable benchmark for fatty acid catabolism and biomarker studies. Protocol integration and solubility parameters make it indispensable for translational metabolic investigations.

• NIR-Triggered Cobalt Single-Atom Enzyme Boosts Multimodal Ph

  2026-06-19

  This study introduces an atomically dispersed cobalt single-atom enzyme (Co-SAE) on hollow N-doped carbon spheres as a near-infrared (NIR)-responsive multimodal phototherapy agent for head and neck cancer. By integrating photodynamic, photocatalytic, and photothermal effects, the approach amplifies reactive oxygen species (ROS) production and mild hyperthermia, providing a synergistic and less invasive therapeutic option.

• Osteoblast ECM1 Drives Anti-Androgen Resistance in Bone Meta

  2026-06-18

  This study uncovers how osteoblast-derived ECM1, secreted in response to enzalutamide therapy, activates the ENO1-MAPK axis and promotes anti-androgen resistance in bone metastatic prostate cancer. The findings reveal a non-tumor cell autonomous mechanism that could inform the development of new therapeutic strategies targeting the tumor microenvironment.

• M344: Histone Deacetylase Inhibitor for Cancer Workflows

  2026-06-18

  M344, a potent histone deacetylase inhibitor, enables precise modulation of epigenetic states in cancer and HIV latency models. Its robust action in neuroblastoma and breast cancer workflows delivers both differentiation and cytotoxicity, giving researchers a streamlined choice for advanced epigenetic interrogation.

• AZD2461: Advancing PARP Inhibitor Strategies in Breast Cance

  2026-06-17

  This thought-leadership article explores how AZD2461, a next-generation PARP inhibitor from APExBIO, is redefining translational research paradigms in breast cancer. By integrating mechanistic insights into PARP-1 inhibition, DNA repair pathway modulation, and the strategic circumvention of Pgp-mediated resistance, we provide actionable experimental guidance and a roadmap for leveraging AZD2461 to overcome established limitations in drug response evaluation and BRCA1-mutated tumor models.

• Moxifloxacin in Antibiotic Toxicity and Retinal Research Wor

  2026-06-17

  Moxifloxacin stands out as a broad-spectrum fluoroquinolone antibiotic for probing antibiotic toxicity, retinal ganglion cell viability, and metabolic immune responses. This guide translates reference breakthroughs and real-world protocols into actionable insights, enabling researchers to tackle advanced cytotoxicity and metabolic response assays with confidence.

• Ranolazine: Anti-Ischemic Agent Workflows & Troubleshooting

  2026-06-16

  Ranolazine stands out in cardiac ischemia research by combining late sodium current inhibition with unique metabolic modulation. This guide details advanced experimental workflows, practical optimization, and troubleshooting strategies, empowering researchers to maximize both translational and mechanistic insights.

• Metal Ion-Mediated Enrichment Boosts mRNA Vaccine Loading

  2026-06-16

  The referenced study introduces a manganese ion-mediated strategy to condense mRNA, enabling nearly double the mRNA loading in lipid nanoparticle vaccines compared to conventional formulations. This innovation addresses key toxicity and efficacy limitations in current mRNA vaccine delivery systems, with implications for safer and more potent mRNA therapeutics.

• Quizartinib (AC220): Reframing FLT3 Inhibition for Translati

  2026-06-15

  This expert article dissects the mechanistic, strategic, and translational implications of Quizartinib (AC220) as a next-generation FLT3 inhibitor, illuminating how its nanomolar selectivity and robust preclinical profile empower acute myeloid leukemia (AML) research. Drawing on recent findings that link FLT3 signaling to drug resistance in blast phase CML, the discussion offers actionable guidance on experimental design, protocol parameters, and resistance modeling, while critically assessing opportunities and boundaries for translational researchers. By bridging clinical insights with innovative laboratory workflows and referencing both foundational and advanced guides, APExBIO’s Quizartinib (AC220) is positioned as a pivotal tool for deciphering the evolving landscape of FLT3-targeted therapies.

• Nile Red in Biomarker-Driven Lipidomics: Beyond Conventional

  2026-06-15

  Explore how Nile Red, a dual-emission lipophilic fluorescent dye, revolutionizes intracellular lipid droplet staining and lipid metabolism research. This article uniquely connects Nile Red’s advanced applications to biomarker discovery in cancer, revealing new assay strategies for translational lipidomics.

• Inhibiting Extracellular Vesicle Release in Triple-Negative

  2026-06-14

  McNamee et al. performed a systematic analysis of calpain and other pathway inhibitors to block extracellular vesicle (EV) release in triple-negative breast cancer (TNBC) cell lines. Their work demonstrates that broad suppression of EV release—achieved by agents like Calpeptin—can significantly reduce the transmission of malignant phenotypic traits, highlighting a potential strategy to interrupt tumor cell communication.

• Dexamethasone (DHAP): Glucocorticoid Anti-Inflammatory Preci

  2026-06-13

  Dexamethasone (DHAP) is a synthetic glucocorticoid anti-inflammatory compound that modulates immune signaling and cellular differentiation. It inhibits NF-κB signaling and promotes autophagy, making it a benchmark tool in inflammation and neuroinflammation research.

• Pregnenolone Carbonitrile: Applied Workflows in Liver and PX

  2026-06-12

  Pregnenolone Carbonitrile is setting the standard for advanced hepatic and PXR-driven studies, enabling researchers to dissect xenobiotic metabolism, antifibrotic pathways, and gut-liver crosstalk. Recent findings on its microbiota-mediated hepatoprotection further expand its translational relevance for modeling complex liver disease.

• Targeting CaN/FoxO1/FABP4 Pathway Mitigates SERCA2-Driven At

  2026-06-12

  This study reveals that SERCA2 C674S mutation promotes atherosclerosis by activating the calcineurin/FoxO1/FABP4 axis, leading to foam cell formation and aberrant lipid metabolism. Pharmacological inhibition of FABP4 interrupts this pathogenic cascade, providing a focused mechanistic rationale for targeting FABP4 in cardiovascular research.

452 records 14/31 page Previous Next First page 上5页 1112131415 下5页 Last page